MARLBOROUGH, Mass., May 27, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 8:00 a.m. EDT. Dr. Cauwenbergh will discuss the development of RXI-109, a self-delivering RNAi compound designed to reduce dermal scarring, as well as business development opportunities with RXi's sd-rxRNA® technology platform.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
The presentation will be webcast and available on the "Investors" section of the Company's website, www.rxipharma.com.
About Jefferies 2014 Global Healthcare Conference
This conference will feature an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare IT and medical technology sectors, with over 300 participating companies and 2,500 attendees. This global gathering of leading executives, institutional investors, private equity investors and VCs will address near- and long-term investment opportunities and discuss the mechanisms driving healthcare in the U.S. and internationally. This conference will take place June 2-5, 2014 in New York City.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate the expression of specific genes that may be over-expressed in disease conditions. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the Company's Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, entered into human clinical trials in June 2012 and is currently in Phase 2. RXI-109 targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis). For more information, please visit www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks and uncertainties: the risk that we may not be able to successfully develop our candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based products; risks that the development process for our product candidates may be delayed, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
SOURCE RXi Pharmaceuticals Corporation